国际标准期刊号: 2167-065X

临床药理学与生物药剂学

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • Genamics 期刊搜索
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Stem Cell Approaches for Treatment of Neurodegenerative Diseases

Saurabh Anand and Kiminobu Sugaya

Neurodegenerative diseases are devastating age-related disorders severely affecting the patient, caregivers, and enormously increasing the financial burden of the nation. Despite decades of hard work both in laboratory and clinic, the effective treatment specifically designed for a patient is still far from reach. Stem cell therapy, though with several challenges including limited differentiation potential of adult stem cells, ethical issues with using embryonic and fetal stem cells, tumor formation upon transplantation of cells, etc., offers enormous potential for treatment of several neurodegenerative diseases. Pharmacological drugs currently available in the market on the other hand are mainly for alleviating the symptoms and not for treating the disease per se. The efficiency of drug delivery across the bloodbrain barrier, stability, efficacy, and side effects these drugs show on patients are some of the hurdles pharmacological approach has to overcome. A detailed understanding of these complicated diseases at molecular level followed by the right combination of specifically tailored stem cell therapy and/or effective drugs e.g. MS-818 used to increase the endogenous stem cell population might be the best course of action in coming years for patients with little time left after their diagnosis.